RA Capital Management, an investment firm, led a $90m Series C round in SpyGlass Pharma, a privately-held ophthalmic therapeutics companywith participation from New Enterprise Associates, Vensana Capital, Samsara BioCapital and Vertex Ventures. “We believe our approach represents a paradigm shift in the treatment of eye diseases, such as glaucoma, with significant advantages compared to currently commercialized therapies. The efficacy and safety demonstrated from the first-in-human feasibility trial showing 45% mean IOP-lowering in glaucoma patients, with 100% of subjects off all topical medication 9 months after implantation, is remarkable," Malik Y. Kahook, SpyGlass Pharma MD, Co-Founder and President.